…
JD Health International Inc., an investment holding company, engages in the operation of an online healthcare platform in the People's Republic of China and internationally. It offers pharmaceutical and healthcare products, including OTC drugs, prescription drugs, and medical devices and supplies, as well as health supplements and tonics through direct selling and an online retail pharmacy network. The company also provides online medical consultation, consumer healthcare, and health management services; hospital or doctor referral, health check-ups, genetic testing, and beauty care services; and intelligent healthcare solutions, as well as technical and advertising services. In addition, it is involved in order management, client management, and other merchants operational and maintenance support activities. The company was incorporated in 2018 and is headquartered in Beijing, the People's Republic of China. JD Health International Inc. operates as a subsidiary of JD Jiankang Limited.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
JD Health International Inc provides online healthcare and pharmacy services in China, including telemedicine, prescription fulfillment and health-management offerings via a digital platform linked to JD.com's e-commerce and logistics network. Long-term growth may be supported by China's aging population, rising digital-health adoption and the shift of pharmacy and chronic-care services online, with scale and platform integration appearing to support market penetration.
Key risks are regulatory and policy shifts in China's healthcare and internet sectors, intense competition from other tech-backed healthcare providers, and execution and profitability pressure as the company expands.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 695.81M | -901.49M | -17072.14M | -834.70M | 306.23M |
| Minority interest | -3.12M | -0.69M | 0.53M | 0.00M | 0.00M |
| Net income | 380.11M | -1073.51M | -17234.36M | -971.80M | 214.93M |
| Selling general administrative | 2153.53M | 5536.22M | 2521.93M | 1247.63M | 1029.13M |
| Selling and marketing expenses | 2195.76M | 2133.84M | 1434.59M | 746.01M | 391.82M |
| Gross profit | 9891.51M | 7197.28M | 4917.30M | 2812.27M | 1978.96M |
| Reconciled depreciation | 140.68M | 63.17M | 27.22M | 7.42M | 6.27M |
| Ebit | 803.11M | -857.14M | -17068.61M | -797.34M | 310.77M |
| Ebitda | 943.79M | -793.97M | -17041.39M | -789.92M | 317.03M |
| Depreciation and amortization | 140.68M | 63.17M | 27.22M | 7.42M | 6.27M |
| Operating income | 803.11M | -857.14M | -17068.61M | -797.34M | 310.77M |
| Other operating expenses | 46783.07M | 32047.96M | 19030.85M | 10408.70M | 7861.94M |
| Interest expense | 9.10M | 6.00M | 3.42M | 35.50M | 0.15M |
| Tax provision | 312.58M | 171.33M | 162.76M | 137.10M | 91.31M |
| Interest income | 864.27M | 457.57M | 149.12M | 31.78M | 0.08M |
| Net interest income | 855.17M | 451.57M | 145.70M | -3.72M | -0.07M |
| Income tax expense | 312.58M | 171.33M | 162.76M | 137.10M | 91.31M |
| Total revenue | 46736.15M | 30682.27M | 19382.57M | 10842.14M | 8169.06M |
| Total operating expenses | 9938.43M | 8562.98M | 4565.58M | 2378.83M | 1671.84M |
| Cost of revenue | 36844.64M | 23484.99M | 14465.27M | 8029.87M | 6190.10M |
| Total other income expense net | -107.30M | -44.35M | -3.53M | -37.36M | -4.54M |
| Net income from continuing ops | 383.23M | -1072.82M | -17234.90M | -971.80M | 214.93M |
| Net income applicable to common shares | - | -1073.51M | -17234.36M | -971.80M | 214.93M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 61277.30M | 48002.22M | 43994.55M | 8676.68M | 1182.15M |
| Other current assets | 757.41M | 8.61M | 4.52M | 2.50M | 3.02M |
| Total liab | 16492.73M | 8147.63M | 4743.20M | 9135.71M | 432.93M |
| Total stockholder equity | 44780.25M | 39853.39M | 39250.84M | -459.03M | 749.22M |
| Other current liab | 5759.48M | 2452.41M | 1753.63M | 1095.04M | 89.57M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 2.00M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 2.00M |
| Retained earnings | -19382.06M | -19714.84M | -18616.76M | -1368.79M | -94.77M |
| Other liab | - | 8.89M | - | - | - |
| Other assets | 787.45M | 979.65M | 432.13M | 28.39M | 1.27M |
| Cash | 18717.72M | 17252.29M | 32270.79M | 4965.27M | 16.21M |
| Total current liabilities | 16356.15M | 8005.03M | 4681.79M | 1544.88M | 430.51M |
| Net debt | -18518.31M | -17051.03M | -32180.81M | -4954.01M | -13.09M |
| Short term debt | 70.65M | 67.55M | 28.57M | 4.85M | 0.71M |
| Short long term debt total | 199.41M | 201.27M | 89.98M | 11.26M | 3.13M |
| Other stockholder equity | 64162.30M | 59568.22M | 57867.59M | 909.75M | 841.99M |
| Property plant equipment | - | 260.77M | 115.01M | 16.20M | 4.37M |
| Total current assets | 56447.16M | 45705.48M | 42704.77M | 8624.04M | 1166.34M |
| Net tangible assets | - | 39828.00M | 39222.35M | -459.63M | 746.46M |
| Short term investments | 28248.49M | 24737.78M | 8032.61M | 1395.24M | - |
| Net receivables | 2727.27M | 665.54M | 664.46M | 982.70M | 31.80M |
| Inventory | 5996.27M | 3041.24M | 1732.39M | 1278.34M | 1115.30M |
| Accounts payable | 10526.03M | 5485.07M | 2899.60M | 444.98M | 340.23M |
| Non currrent assets other | 28727.07M | 25473.60M | 8282.98M | 1422.43M | 7.73M |
| Non current assets total | 4830.14M | 2296.74M | 1289.78M | 52.63M | 15.81M |
| Capital lease obligations | 199.41M | 201.27M | 89.98M | 11.26M | 3.13M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -4235.54M | -17247.24M | -7558.57M | -1440.91M | -7.41M |
| Change to liabilities | 6020.50M | 2801.42M | 2539.91M | 151.92M | 176.87M |
| Total cashflows from investing activities | - | -17752.15M | -7842.58M | -1448.62M | -13.69M |
| Net borrowings | -47.56M | -32.33M | -242.92M | 200.70M | -2.77M |
| Total cash from financing activities | -925.45M | -163.65M | 32028.69M | 6509.12M | -2.92M |
| Change to operating activities | 665.08M | 843.36M | 945.75M | 43.12M | 4.03M |
| Net income | 383.23M | -1072.82M | -17234.90M | -971.80M | 214.93M |
| Change in cash | 1465.43M | -15018.50M | 27305.52M | 4949.06M | 8.81M |
| Begin period cash flow | 17252.29M | 32270.79M | 4965.27M | 16.21M | 7.40M |
| End period cash flow | 18717.72M | 17252.29M | 32270.79M | 4965.27M | 16.21M |
| Total cash from operating activities | 5905.15M | 3430.72M | 3699.46M | 409.47M | 187.23M |
| Issuance of capital stock | - | 0.00M | 32274.05M | 6310.66M | 0.00M |
| Depreciation | 140.68M | 63.17M | 27.22M | 7.42M | 6.27M |
| Other cashflows from investing activities | -5.41M | 5.18M | -242.91M | -2.03M | -3.86M |
| Change to inventory | -3151.38M | -1286.16M | -522.21M | -164.03M | -232.37M |
| Change to account receivables | -685.08M | -331.40M | -47.66M | -3.38M | -21.33M |
| Sale purchase of stock | -869.03M | -126.41M | - | - | - |
| Other cashflows from financing activities | -56.41M | -37.25M | 6242.70M | 6509.11M | -2.92M |
| Change to netincome | 2535.23M | 2413.84M | 17990.80M | 1346.21M | 38.83M |
| Capital expenditures | 2272.95M | 518.16M | 38.79M | 5.69M | 2.42M |
| Change in working capital | 2849.14M | 2027.21M | 2915.80M | 27.64M | -72.80M |
| Stock based compensation | 2104.28M | 2579.71M | 380.30M | 52.73M | 33.47M |
| Other non cash items | 427.83M | -166.55M | 17611.04M | 1293.48M | 5.36M |
| Free cash flow | 3632.20M | 2912.56M | 3660.68M | 403.78M | 184.81M |
Sector: Healthcare Industry: Medical Care Facilities
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| JDHIY JD Health International Inc |
- -% |
5.28 | 62.50 | 35.97 | 0.30 | 2.32 | 0.16 | 3.90 |
| HCA HCA Healthcare, Inc. |
-12.31 2.43% |
495.17 | 14.27 | 13.46 | 1.21 | 291.34 | 1.83 | 8.99 |
| THC Tenet Healthcare Corporation |
-2.95 1.03% |
283.51 | 10.08 | 12.66 | 0.96 | 4.57 | 1.43 | 5.80 |
| FSNUY Fresenius SE & Co KGaA ADR |
0.02 0.14% |
14.44 | 16.87 | 9.44 | 0.42 | 0.78 | 0.79 | 5.37 |
| FMCQF Fresenius Medical Care AG & Co. KGaA |
- -% |
47.84 | 14.21 | 9.00 | 0.78 | 0.77 | 0.98 | 5.67 |
JD Health International Inc., an investment holding company, engages in the operation of an online healthcare platform in the People's Republic of China and internationally. It offers pharmaceutical and healthcare products, including OTC drugs, prescription drugs, and medical devices and supplies, as well as health supplements and tonics through direct selling and an online retail pharmacy network. The company also provides online medical consultation, consumer healthcare, and health management services; hospital or doctor referral, health check-ups, genetic testing, and beauty care services; and intelligent healthcare solutions, as well as technical and advertising services. In addition, it is involved in order management, client management, and other merchants operational and maintenance support activities. The company was incorporated in 2018 and is headquartered in Beijing, the People's Republic of China. JD Health International Inc. operates as a subsidiary of JD Jiankang Limited.
| Name | Title | Year Born |
|---|---|---|
| Mr. Enlin Jin | CEO & Exec. Director | 1981 |
| Mr. Dong Cao | Chief Financial Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.